Cas:501-53-1 Benzyl chloroformate manufacturer & supplier

We serve Chemical Name:Benzyl chloroformate CAS:501-53-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Benzyl chloroformate

Chemical Name:Benzyl chloroformate
CAS.NO:501-53-1
Synonyms:Benzyl carbonochloridoate;carbonochloridic acid benzyl ester;Formic acid, chloro-, benzyl ester (8CI);phenylmethyl chloroformate;Benzyl carbonochloridate;Bzcf;CBZ-Cl (Z-Cl);Carbonochloridic acid phenylmethyl ester;Z-CHLORIDE;Z-Cl (Cbz-Cl);Benzyl chlorocarbonate;Cbz chloride;Z-CL;Benzyl Chlorofomate;MFCD00000640;Chloroformic acid benzyl ester;CBZ;CBZ-Cl;EINECS 207-925-0;Benzyl chloroformate;Benzylchloroformate;Benzyl Chloroformate,Carboobenzoxy Chloride;Benzyloxycarbonyl chloride;Carbonochloridic acid, phenylmethyl ester;BCF;(benzyloxy)carbonyl chloride;Benzylcarbonochloridate;Benzylchlorformiat;Carbobenzyloxy chloride;carbobenzoxy chloride
Molecular Formula:C8H7ClO2
Molecular Weight:170.593
HS Code:2915900090

Physical and Chemical Properties:
Melting point:-20 °C
Boiling point:224.0±19.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.531
PSA:26.30000
Exact Mass:170.013458
LogP:2.68

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2924 3/PG 2
Packing Group:I


Contact us for information like Benzyl carbonochloridoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,carbobenzoxy chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzyl Chlorofomate Use and application,Benzyl carbonochloridate technical grade,usp/ep/jp grade.


Related News: TULIP-2 demonstrated superiority across multiple efficacy endpoints versus placebo with both arms receiving standard therapy. barium pentafluoromanganate(III) manufacturers AstraZeneca acquired global rights to anifrolumab through an exclusive license and collaboration agreement with Medarex, Inc. in 2004. Medarex was acquired by Bristol-Myers Squibb in 2009. 1-((5-(5-chlorothiophen-2-yl)isoxazol-3-yl)methyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid suppliers The review considered two cases of AML in patients treated with an investigational medicine, bb1111, in a clinical trial for sickle cell disease. Although there have been no reports of AML with Zynteglo, both medicines use the same viral vector and there was a concern that the vector may be implicated in the development of the cancer (insertional oncogenesis). 17β-Acetoxy-16α-ethyl-3-methoxyestra-1,3,5(10)-trien vendor & factory.